ArticleJournal of gastroenterology2024
Cancer risk by length of Barrett's esophagus in Japanese population: a nationwide multicenter retrospective cohort study.
Article in Journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Natural history of Barrett's esophagus over a 10-year period: a longitudinal endoscopic study in a Japanese population.Journal of gastroenterology · 2026Article
- A Ruler Needs a Zero Point: Defining the Gastroesophageal Junction for Length-Based Risk Stratification in Barrett's Esophagus.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Article
- Five-Year Unified Risk Prediction Model for Gastric and Esophageal Cancer Based on Nationwide Health Check-Up Data in Japan: J-GESS Score.Journal of gastroenterology and hepatology · 2026Article
- A steadily increasing trend in the incidence of esophageal adenocarcinoma in Akita Prefecture, Japan, through 2024.Journal of gastroenterology · 2026Article
- Clinical relevance of the identification of the distal end of the palisade vessel in cases with columnar-lined esophagus: a comment on the study by Hatta et al.Journal of gastroenterology · 2026Article
- How Many Biopsies Are Enough? Rethinking Biopsy and Surveillance Strategies for Barrett's Esophagus in Asia.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Article
- Review
- Endoscopic spectrum of autoimmune gastritis across disease stages: a focus on Barrett's esophagus and ME-NBI features.Frontiers in immunology · 2026Article
- Etiology and Pathophysiology of Barrett's Esophagus/Neoplasia.Digestion · 2026Review
- Evaluating the discrepancies between evidence-based and community standard practices in the endoscopic examination of Barrett's esophagus: a nationwide survey in Japan.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Age distribution and risk factors for Barrett's esophagus by sex at health check-up settings in Japan.Journal of gastroenterology · 2025Article
- Refining risk assessment in Barrett's esophagus: addressing follow-up and diagnostic limitations.Journal of gastroenterology · 2025Article
- Cox proportional hazards regression reveals more than a 100-fold difference in cancer risk by the length of Barrett's esophagus in Japan.Journal of gastroenterology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cancer risk for each length of Barrett's esophagus (BE) in Japanese is unknown. This nationwide, multi-institutional study aims to clarify the cancer risk by length of BE in the general Japanese population.
methodsConsecutive subjects who underwent upper endoscopic screening at 17 centers between 2013 and 2017 and had at least one follow-up endoscopy by December 2022 were included. The presence/absence of BE and, if present, its length were retrospectively assessed using the retrieved endoscopic images recorded at baseline. Information on the subsequent occurrence of esophageal adenocarcinoma and other upper gastrointestinal cancers was also collected. Cancer incidence was calculated and expressed as %/year.
resultsA total of 33,478 subjects were enrolled, and 17,884 (53.4%), 10,641 (31.8%), 4889 (14.6%), and 64 (0.2%) were diagnosed as absent BE, BE < 1 cm, 1-3 cm, and ≥ 3 cm, respectively. During a median follow-up of 80 months, 11 cases of esophageal adenocarcinoma developed. The annual incidence of esophageal adenocarcinoma is 0%/year for absent BE, 0.0032 (0.00066-0.013)%/year for BE < 1 cm, 0.026 (0.011-0.054)%/year for 1-3 cm, and 0.58 (0.042-2.11)%/year for ≥ 3 cm, respectively. Meanwhile, the incidence of esophageal squamous cell carcinoma and gastric cancer were 0.039 (0.031-0.049)%/year and 0.16 (0.14-0.18)%/year, respectively.
conclusionsBy enrolling a large number of subjects with long-term follow-up, this study demonstrated that the risk of cancer increased steadily with increasing length of BE in the Japanese population. Therefore, it is important to consider the length of BE when determining the management strategy for BE.
Indexed as
Identifiers
39150527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.